Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk
Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to explore if perioperative lidocaine infusion decreases disease reoccurrence and metastasis risk in non-small cell lung cancer patients.
Participants will be randomly assigned (1:1) to the lidocaine or placebo group. The intervention initiates within 30 minutes before anesthesia induction with an intravenous loading dose of 1.5 mg/kg administered over 10-20 minutes. This is followed by a continuous maintenance infusion of 1.5-3 mg/kg/h (calculated as 1-1.5 mg/kg/h in protocol text, see note below) during surgery, terminating 1 hour after skin closure. Participants will be followed up for 36 months post-surgery. Blood samples will be collected at baseline, postoperative day 1, day 3, and upon discharge
Phase:
NA
Details
Lead Sponsor:
First Affiliated Hospital of Ningbo University
Collaborators:
Ningbo Medical Center Lihuili Hospital Second Affiliated Hospital of Wenzhou Medical University Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University